Company Overview of Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company’s product candidates in preclinical stage include INT-767, a...
450 West 15th Street
New York, NY 10011
Founded in 2002
Key Executives for Intercept Pharmaceuticals, Inc.
Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $934.0K
Chief Financial Officer, Treasurer and Secretary
Total Annual Compensation: $556.9K
Chief Medical Officer and Executive Vice President of Development
Total Annual Compensation: $626.5K
Compensation as of Fiscal Year 2013.
Intercept Pharmaceuticals, Inc. Key Developments
Intercept Pharmaceuticals, Inc. Appoints Juan Carlos Lopez-Talavera as Senior Vice President of Medical Affairs
Jun 22 15
Intercept Pharmaceuticals, Inc. announced the appointment of Juan Carlos Lopez-Talavera, M.D., Ph.D. as Senior Vice President of Medical Affairs. Dr. Lopez-Talavera most recently served as Head of Hepatology R&D and Vice President of Medical Affairs at Abbvie, where he was responsible for all Medical Affairs activities supporting the global launch of Abbvie's regimen for the treatment of Hepatitis C.
Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH
May 19 15
Intercept Pharmaceuticals, Inc. announced its plans for an international Phase 3 trial of obeticholic acid (OCA), the company's lead FXR a gonist, in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis. OCA has received breakthrough therapy designation in this patient population from the U.S. Food and Drug Administration (FDA). In accordance with harmonized advice from the FDA and European Medicines Authority (EMA), the Randomized Global Phase 3 Trial to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment (REGENERATE) has been designed as a double-blind, placebo-controlled pivotal Phase 3 clinical trial expected to enroll up to approximately 2,500 patients and assess the potential benefit of OCA treatment on liver-related clinical outcomes. The trial will include a pre-planned interim histology analysis after 72 weeks of treatment in approximately 1,400 patients which is intended to serve as the basis for seeking U.S. and international marketing approvals of OCA for the treatment of NASH patients with liver fibrosis. The REGENERATE trial will be conducted at approximately 250 centers in North America, Europe and other regions and trial initiation is anticipated in third quarter of 2015. Patients will be randomized 1:1:1 to one of placebo, 10 mg of OCA, or 25 mg of OCA, taken once daily. The study population will primarily be comprised of NASH patients with stage 2 or stage 3 advanced liver fibrosis who will be evaluated on the primary efficacy endpoints in the 72-week interim analysis and subsequently. In addition, a relatively small group of NASH patients with stage 1 early liver fibrosis with an increased risk of rapid progression due to concomitant diabetes, obesity or active liver inflammation indicated by elevated ALT will also be enrolled, but not included in the primary endpoint analyses. The interim analysis after 72 weeks of treatment in approximately 1,400 patients will be conducted on the following co-primary endpoints, which are intended to serve as the basis for seeking U.S. and international marketing approvals: the proportion of OCA-treated patients relative to placebo achieving at least one stage of liver fibrosis improvement with no worsening NASH; and the proportion of OCA-treated patients relative to placebo achieving NASH resolution with no worsening of liver fibrosis. Additional supportive histologic endpoints and non-invasive markers of liver fibrosis and steatohepatitis will also be evaluated. The REGENERATE trial will remain blinded after the interim analysis and continue to follow patients until the occurrence of a pre-specified number of adverse liver-related clinical events, including progression to cirrhosis, to confirm clinical benefit on a post-marketing basis.
Intercept Pharmaceuticals, Inc. - Special Call
May 19 15
To discuss aspects of the planned Phase 3 trial
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|